Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma

Camrelizumab is a humanized monoclonal antibody (mAb) that specifically binds to programmed cell death receptor 1 (PD-1), being developed for the treatment of various cancer types including advanced hepatocellular carcinoma (HCC). The recommended dosage of camrelizumab is 200 mg every two weeks (Q2W) in combination with rivoceranib for HCC.